READILY AVAILABLE TECHNOLOGY COULD BE DEPLOYED TO SURFACE UNVACCINATED PATIENTS TO GROUPS ABLE AND EAGER TO ADDRESS THE GAP IN A PERSONALISED AND TARGETED APPROACH .
H E A L T H I N S I G H T S
Systems supported by data sharing agreements , such as EMIS ’ Pathway clinical intelligence software , enable healthcare teams to identify cohorts of at-risk patients . Or in this example , anyone yet to receive the HPV vaccination – for intervention and to support the transfer and surfacing of relevant health information to whoever has the responsibility and capacity to act on it .
READILY AVAILABLE TECHNOLOGY COULD BE DEPLOYED TO SURFACE UNVACCINATED PATIENTS TO GROUPS ABLE AND EAGER TO ADDRESS THE GAP IN A PERSONALISED AND TARGETED APPROACH .
The technology is powerful . It is being used to reach a cohort of people that were previously deemed unreachable to help support NHS England ’ s drive to find and treat those unknowingly living with Hepatitis C . Ultimately to eliminate a disease that too often develops to become life-threatening . It ’ s not just about using technology to make it easier to identify who hasn ’ t had the HPV vaccine .
Clinical intelligence could also help us identify vaccination trends and themes that need to be addressed to improve uptake .
Using this insight to tackle health inequalities would be key .
Female cervical cancer incidence rates in England are 65 % higher in the most deprived quintile compared with the least and women
18 www . intelligenthealth . tech